

## KAPSPARGO SPRINKLE - (EQ 25MG TARTRATE,EQ 50MG TARTRATE,EQ 100MG TARTRATE,EQ 200MG TARTRATE ; CAPSULE,EXTENDED RELEASE)

<b>Generic Name</b>	METOPROLOL SUCCINATE	<b>Innovator</b>	Spil
<b>Dosage</b>	EQ 25MG TARTRATE,EQ 50MG TARTRATE,EQ 100MG TARTRATE,EQ 200MG TARTRATE ; CAPSULE,EXTENDED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	KAPSPARGO Sprinkle is a beta1-selective adrenoceptor blocking agent indicated for the treatment of: ? Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ? Angina Pectoris. ? Heart Failure, to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events



Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.